The Inclisiran Impact on PCSK9: A Primary Care Primer
ACC.24: Michael Koren, MD, highlights how the nonstatin lipid-lowering medication's mechanism of action against PCSK9 differs from others in the category.
Michael J Koren, MD, primary investigator of the VICTORION-INITIATE study of an "inclisiran first" strategy to reduce LDL-C in individuals with ASCVD, differentiates the small-interfering RNA molecule from other agents that reduce the impact of PCSK9 on the cardiovascular system.
Michael J Koren, MD, primary investigator of the VICTORION-INITIATE study, is a cardiologist and serves as the chief executive officer at ENCORE Research Group, in Jacksonville, FL. Koren founded ENCORE in 1997 and since then the organization has conducted more than 2500 clinical trials across 8 locations in Florida.
Recent Videos
Related Content
